Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Analysis: How The Industry Is Evolving Toward A $6.98 Billion Future
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The adeno-associated virus (avv) vectors in gene therapy market size has seen rapid growth recently. It is projected to increase from $3.16 billion in 2025 to $3.7 billion in 2026, at a compound annual growth rate (CAGR) of 17.3%. This historical expansion is attributable to several key factors, including advancements in viral vector safety, increased research into rare genetic disorders, successful outcomes in clinical gene therapy, a rise in regulatory approvals, and substantial investments in academic research.
The adeno-associated virus (avv) vectors in gene therapy market is anticipated to experience significant expansion over the next few years. Its valuation is projected to reach $6.99 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 17.2%. This growth during the forecast period can be attributed to the launch of commercial gene therapies, the demand for scalable vector production, the expansion of precision medicine, incentives for orphan drugs, and an increase in global clinical trials. Major trends expected within this period include the broadening of gene augmentation therapies, a rising need for gene treatments for rare diseases, the development of in vivo gene delivery, a surge in commercial-scale vector manufacturing, and a focus on long-term therapeutic durability.
Get A Free Sample Report With In-Depth Market Insights:
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth Backed By Core Demand Fundamentals
The increasing emphasis on gene-based therapies is projected to boost the adeno-associated virus (AAV) vectors within the gene therapy market going forward. Gene-based therapies are treatments designed to modify or manipulate genes to prevent, treat, or cure diseases at the molecular level. Progress in genetic research is fueling the intensified focus on developing gene-based therapies, as these advancements improve the precision and effectiveness of gene editing techniques. Adeno-associated virus (AAV) vectors in gene therapy assist in creating gene-based therapies by delivering therapeutic genes safely and efficiently into target cells, attributable to their low immunogenicity and ability to provide long-term gene expression. For instance, in 2023, according to IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, global spending on cell and gene therapies amounted to $5.9 billion, representing a 38% increase from 2022. Consequently, the growing focus on creating gene-based therapies is driving the expansion of the adeno-associated virus (AAV) vectors market.
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Segment Trends And Revenue Contributors
The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –
1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy
2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Scale of Operation: Preclinical, Clinical, Commercial
4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area
Subsegments:
1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders
2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering
3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Growth Trends Reshaping The Competitive Landscape
Leading companies in the adeno-associated virus (AAV) vectors in the gene therapy market are concentrating on advanced innovations, such as tailored vector diversity for assay versatility, to improve target tissue specificity, enhance therapeutic effectiveness, and accelerate the creation of personalized gene therapies across various indications. Tailored vector diversity for assay versatility involves employing multiple AAV serotypes or constructs to support diverse analytical tests and therapeutic applications. For instance, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, unveiled new reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV), designed to meet the expanding demands of cell and gene therapy (CGT) development. This portfolio aims to facilitate a smoother progression from early-stage research to GMP-grade production, aiding in standardizing processes and enhancing consistency in viral vector manufacturing. This introduction directly addresses a primary challenge in advancing CGT programs towards clinical and commercial readiness.
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.
View The Full Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report:
Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2025. The regions covered in the adeno-associated virus (avv) vectors in gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
